- Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD more...
Hepatitis C is an infection caused by the hepatitis C virus (HCV) that attacks the liver and leads to inflammation. The World Health Organization (WHO) estimates that about 3% of the world’s population has been infected with HCV and that there are more than 170 million chronic carriers who are at risk of developing liver cirrhosis and/or liver cancer. The image below depicts the HCV genome.
Signs and symptoms
Initial symptoms of hepatitis C are often extrahepatic, most commonly involving the joints, muscle, and skin. Examples include the following:
- Sicca syndrome
- Sensory neuropathy
Symptoms characteristic of complications from advanced or decompensated liver disease are related to synthetic dysfunction and portal hypertension, such as the following:
- Mental status changes (hepatic encephalopathy)
- Ankle edema and abdominal distention (ascites)
- Hematemesis or melena (variceal bleeding)
Physical findings usually are not abnormal until portal hypertension or decompensated liver disease develops. Signs in patients with decompensated liver disease include the following:
- Hand signs: Palmar erythema, Dupuytren contracture, asterixis, leukonychia, clubbing
- Head signs: Icteric sclera, temporal muscle wasting, enlarged parotid gland, cyanosis
- Fetor hepaticus
- Gynecomastia, small testes
- Abdominal signs: Paraumbilical hernia, ascites, caput medusae, hepatosplenomegaly, abdominal bruit
- Ankle edema
- Scant body hair
- Skin signs: Spider nevi, petechiae, excoriations due to pruritus
Other common extrahepatic manifestations include the following:
- Cryoglobulinemia: Membranoproliferative glomerulonephritis
- Lichen planus
- Keratoconjunctivitis sicca
- Raynaud syndrome
- Sjögren syndrome
- Porphyria cutanea tarda
- Necrotizing cutaneous vasculitis
- Non-Hodgkin lymphoma
See Clinical Presentation for more detail.
See 5 Body Modifications and Piercing: Dermatologic Risks and Adverse Reactions, a Critical Images slideshow, to help recognize various body modifications and the related potential complications.
General baseline studies in patients with suspected hepatitis C include the following:
- Complete blood cell count with differential
- Liver function tests, including alanine aminotransferase level
- Thyroid function studies
- Screening for alcohol abuse, drug abuse, or depression
Tests for detecting hepatitis C virus (HCV) infection include the following:
- Hepatitis C antibody testing: Enzyme immunoassays (EIAs), rapid diagnostic tests (RDTs), and point-of-care tests (POCTs)
- Recombinant immunoblot assay
- Qualitative and quantitative assays for HCV RNA (based on polymerase chain reaction [PCR] or transmission-mediated amplification [TMA])
- HCV genotyping
- Serologic testing (essential mixed cryoglobulinemia is a common finding)
Liver biopsy is not mandatory before treatment but may be helpful. Some restrict it to the following situations:
- The diagnosis is uncertain
- Other coinfections or disease may be present
- The patient has normal liver enzyme levels and no extrahepatic manifestations
- The patient is immunocompromised
See Workup for more detail.
Treatment of acute hepatitis C has rapidly evolved
Hepatitis C is a worldwide problem. The hepatitis C virus (HCV) is a major cause of both acute and chronic hepatitis. The World Health Organization (WHO) estimates about 3% of the world’s population has been infected with HCV and that there are more than 170 million chronic carriers who are at risk of developing liver cirrhosis and/or liver cancer.
The prevalence of HCV infection varies throughout the world. For example, Frank et al reported in 2000 that Egypt had the highest number of reported infections, largely attributed to the use of contaminated parenteral antischistosomal therapy. This led to a mean prevalence of HCV antibodies in persons in Egypt of 22%.
In the United States, the incidence of acute HCV infection has sharply decreased during the past decade. Its prevalence remains high (approximately 2.7 million Americans), however, because chronic hepatitis C (CHC) infection develops in approximately 75% of patients after acute infection.
According to the US Centers for Disease Control and Prevention (CDC), an estimated 1.8% of the US population is positive for HCV antibodies. Because 3 of 4 seropositive persons are also viremic, this corresponds to an estimated 2.7 million people with active HCV infection nationwide.
Infection due to HCV accounts for 20% of all cases of acute hepatitis, an estimated 30,000 new acute infections, and 8000-10,000 deaths each year in the United States. HCV has rapidly surpassed HIV as a cause of death in the US. An examination of nearly 22 million death records over 9 years revealed an HCV mortality rate of 4.58 deaths per 100,000 people per year and an HIV mortality rate of 4.16 deaths per 100,000 people. Almost 75% of HCV deaths occurred among adults between the ages of 45 and 64.
Medical care costs associated with the treatment of HCV infection in the United States are estimated to be more than $600 million a year. Most patients infected with HCV have chronic liver disease, which can progress to cirrhosis and hepatocellular carcinoma (HCC). Chronic infection with HCV is one of the most important causes of chronic liver disease (see the image below) and, according to a report by Davis et al, the most common indication for orthotopic liver transplantation (OLT) in the United States.
Most patients with acute and chronic infection are asymptomatic. Patients and health care providers may detect no indications of the conditions for long periods; however, chronic hepatitis C infection and chronic active hepatitis are slowly progressive diseases and result in severe morbidity in 20-30% of infected persons. Astute observation and integration of findings of extrahepatic symptoms, signs, and disease are often the first clues to underlying HCV infection.
Although acute hepatitis C virus (HCV) infection is usually mild, chronic hepatitis results in at least 75% of patients. (See Prognosis.) While liver enzyme levels may be in the reference range, the presence of persistent HCV-RNA levels discloses chronic infection. Biopsy samples of the liver may reveal chronic liver disease in patients. Cirrhosis develops in 20-50% of patients with chronic hepatitis C infection. Liver failure and hepatocellular carcinoma can eventually result. Hepatocellular carcinoma occurs in 11-19% of patients.
The cause of hepatitis C, HCV, is a spherical, enveloped, single-stranded RNA virus belonging to the Flaviviridae family and Flavivirus genus. The natural targets of HCV are hepatocytes and, possibly, B lymphocytes. Viral clearance is associated with the development and persistence of strong virus-specific responses by cytotoxic T lymphocytes and helper T cells.
In most infected people, viremia persists and is accompanied by variable degrees of hepatic inflammation and fibrosis. Findings from studies suggest that at least 50% of hepatocytes may be infected with HCV in patients with chronic hepatitis C.
RNA-dependent RNA polymerase, an enzyme critical in HCV replication, lacks proofreading capabilities and generates a large number of mutant viruses known as quasispecies. These represent minor molecular variations with only 1-2% nucleotide heterogeneity. HCV quasispecies pose a major challenge to immune-mediated control of HCV and may explain the variable clinical course and the difficulties in vaccine development.
Hepatitis C is caused by a spherical, enveloped, single-stranded RNA virus belonging to the family Flaviviridae, genus Flavivirus. Lauer and Walker reported that HCV is closely related to hepatitis G, dengue, and yellow fever viruses. HCV can produce at least 10 trillion new viral particles each day.
The HCV genome consists of a single, open reading frame and 2 untranslated, highly conserved regions, 5'-UTR and 3'-UTR, at both ends of the genome. The genome has approximately 9500 base pairs and encodes a single polyprotein of 3011 amino acids that are processed into 10 structural and regulatory proteins (see the image below).
Structural components include the core and 2 envelope proteins, E1 and E2. Two regions of the E2 protein, designated hypervariable regions 1 and 2, have an extremely high rate of mutation, thought to result from selective pressure by virus-specific antibodies. The envelope protein E2 also contains the binding site for CD-81, a tetraspanin receptor expressed on hepatocytes and B lymphocytes that acts as a receptor or coreceptor for HCV.
The nonstructural components include NS2, NS3, NS4A, NS4B, NS5A, NS5B, and p7, whose proteins function as helicase-, protease-, and RNA-dependent RNA polymerase, although the exact function of p7 is unknown. One region within NS5A is linked to an interferon (IFN) response and is called the IFN sensitivity–determining region. These enzymes are critical in viral replication and are attractive targets for future antiviral therapy.
HCV genomic analysis by means of arduous gene sequencing of many viruses has led to the division of HCV into 6 genotypes based on homology. Numerous subtypes have also been identified. Arabic numerals denote the genotype, and lower-case letters denote the subtypes for lesser homology within each genotype.
Molecular differences between genotypes are relatively large, and they have a difference of at least 30% at the nucleotide level. The major HCV genotype worldwide is genotype 1, which accounts for 40-80% of all isolates. Genotype 1 also may be associated with more severe liver disease and a higher risk of HCC. Genotypes 1a and 1b are prevalent in the United States, whereas in other countries, genotype 1a is less frequent. HCV genotype 1, particularly 1b, does not respond to therapy as well as genotypes 2 and 3. Genotype details are as follows:
- Genotype 1a occurs in 50-60% of patients in the United States
- Genotype 1b occurs in 15-20% of patients in the United States; this type is most prevalent in Europe, Turkey, and Japan
- Genotype 1c occurs in less than 1% of patients in the United States
- Genotypes 2a, 2b, and 2c occur in 10-15% of patients in the United States; these subtypes are widely distributed and are most responsive to medication
- Genotypes 3a and 3b occur in 4-6% of patients in the United States; these subtypes are most prevalent in India, Pakistan, Thailand, Australia, and Scotland
- Genotype 4 occurs in less than 5% of patients in the United States; it is most prevalent in the Middle East and Africa
- Genotype 5 occurs in less than 5% of patients in the United States; it is most prevalent in South Africa
- Genotype 6 occurs in less than 5% of patients in the United States; it is most prevalent in Southeast Asia, particularly Hong Kong and Macao
Within a region, a specific genotype may also be associated with a specific mode of transmission, such as genotype 3 among persons in Scotland who abuse intravenous drugs.
Transfusion of blood contaminated with HCV was once an important source of transmission. Since 1990, however, the screening of donated blood for HCV antibody has decreased the risk of transfusion-associated HCV infection to less than 1 case in 103,000 transfused units. With the use of more sensitive assays, such as polymerase chain reaction (PCR), Stramer et al reported that the risk of acquiring HCV from blood transfusions is estimated to be 1 in 230,000 donations. The newer assays have decreased the window after infection to 1-2 weeks.
Persons who inject illegal drugs with nonsterile needles or who snort cocaine with shared straws are at highest risk for HCV infection. In developed countries, most new HCV infections are related to intravenous drug abuse (IVDA).
Transmission of HCV to health care workers may occur via needle-stick injuries or other occupational exposures. Needle-stick injuries in the health care setting result in a 3% risk of HCV transmission. According to Rischitelli et al, however, the prevalence of HCV infection among health care workers is similar to that of the general population. Nosocomial patient-to-patient transmission may occur by means of a contaminated colonoscope, via dialysis, or during surgery, including organ transplantation before 1992.
HCV may also be transmitted via tattooing, sharing razors, and acupuncture. The use of disposable needles for acupuncture, which has become standard practice in the United States, eliminates this transmission route.
Yeung et al reported that uncommon routes of transmission of HCV, which affect less than 5% of the individuals at risk, include high-risk sexual activity and maternal-fetal transmission. Coinfection with human immunodeficiency virus (HIV) type 1 appears to increase the risk of both sexual and maternal-fetal transmission of HCV. Casual household contact and contact with the saliva of those infected are inefficient modes of transmission. No risk factors are identified in approximately 10% of cases.
United States statistics
Hepatitis C is the major cause of chronic hepatitis in the United States. HCV infections account for 20% of all cases of acute hepatitis and for more than 40% of all referrals to active liver clinics.
Alter et al reported that HCV infections account for approximately 30,000 new infections and 8000-10,000 deaths each year in the United States. Of new infections, 60% occur in intravenous drug users; less than 20% of new cases are acquired through sexual exposure; and 10% are due to other causes, including occupational or perinatal exposure and hemodialysis.
The overall prevalence of anti-HCV antibodies in the United States is 1.8% of the population. Approximately 74% of these individuals are positive for HCV RNA, meaning that active viral replication continues to occur. Thus, an estimated 3.9 million persons are infected with HCV and 2.7 million persons in the United States have chronic infection. Genotype 1a occurs in 57% of patients; genotype 1b occurs in 17%.
From 1989-1993, the occurrence of HCV to approximately 28,000 new cases per year, reflecting an 80% decrease. Decreased transfusion-associated disease and a dramatic decrease in intravenous drug use accounted for this change.
El-Serag et al reported that HCV is largely responsible for the increase in the incidence of HCC in the United States during the final decades of the 20th century. In the United States, the number of deaths due to HCV-related complications increased from fewer than 10,000 in 1992 to just fewer than 15,000 in 1999. According to Kim, this number is expected to increase in the future because of the current large pool of undiagnosed patients with chronic infection.
Worldwide, more than 170 million persons have hepatitis C virus (HCV) infection. The prevalence rates in healthy blood donors are 0.01-0.02% in the United Kingdom and northern Europe, 1-1.5% in southern Europe, and 6.5% in parts of equatorial Africa. Prevalence rates as high as 22% are reported in Egypt and are attributed to the use of parenteral antischistosomal therapy.
Race-, sex-, and age-related differences in incidence
In the United States, HCV infection is more common among minority populations, such as black and Hispanic persons, than other populations, in association with lower economic status and educational levels. In addition, in the United States, genotype 1 is more prevalent in blacks than in other racial groups.
No sex preponderance occurs with HCV infection. In the third National Health and Nutrition Examination Survey, neither sex nor racial-ethnic group was independently associated with HCV infection.
In the United States, 65% of persons with HCV infection are aged 30-49 years. Those who acquire the infection at a younger age have a somewhat better prognosis than those who are infected later in life. Infection is uncommon in persons aged 20 years and younger and is more prevalent in persons older than 40 years.[14, 15] Data suggest an association between age and transmission route, such as nonsterile medical procedures, including vaccination and parenteral drug treatment.
Infection with HCV is self-limited in only a small minority of infected persons. Chronic infection develops in 70-80% of patients infected with HCV. Cirrhosis develops within 20 years of disease onset in 20% of persons with chronic infection. The onset of chronic hepatitis C infection early in life often leads to less serious consequences.[18, 19] Hepatitis B virus (HBV) coinfection, iron overload, and alpha 1-antitrypsin deficiency may promote the progression of chronic HCV infection to HCV-related cirrhosis.[20, 21]
Two studies of compensated cirrhosis in the United States and Europe showed that decompensation occurred in 20% of patients and that HCC occurred in approximately 10% of patients.[22, 23] The survival rate at 5 and 10 years was 89% and 79%, respectively. HCC develops in 1-4% of patients with cirrhosis each year after an average of 30 years.
The risk of cirrhosis and HCC doubles in patients who acquired HCV infection via transfusion. Progression to HCC is more common in the presence of cirrhosis, alcoholism, and HBV coinfection.
Bellentani et al and Hourigan et al reported that the rate and likelihood of progression is influenced by alcohol use, immunosuppression, sex, iron status, concomitant hepatitis, and age of acquisition (see the image below).
In an observational study of Veterans Affairs (VA) HCV clinical registry data from 128,769 patients, McCombs et al found that those who achieved an undetectable HCV viral load had a decreased risk of subsequent liver morbidity and death.[27, 28] Viral load suppression reduced the risk for future liver events by 27% (eg, compensated/decompensated cirrhosis, hepatocellular carcinoma, or liver-related hospitalization), as well as reduced the risk of death by 45%, relative to patients who did not achieve viral load suppression.[27, 28] Additionally, patient race/ethnicity and HCV genotypes affected the risk of future liver events and death. The risk for all liver events and death was higher in white patients relative to black patients, and those with HCV genotype 3 had a higher risk for all study outcomes compared with patients who had HCV genotype 2 (lowest risk) or 1.[27, 28]
Patients with hepatitis C should be advised to abstain from alcohol use. Optimally, patients should use barrier protection during sexual intercourse.
Patients with hepatitis C should not donate blood or organs. One exception is in patients with HCV who require liver transplantation. Arenas et al showed that liver transplant recipients who received liver grafts from HCV-positive donors had 5-year survival rates comparable to recipients who received grafts from HCV-negative donors. Given the shortage of organs and the long waiting list, this strategy has proven safe and effective.
In August 2012, the Centers for Disease Control and Prevention (CDC) expanded their existing, risk-based testing guidelines to recommend a 1-time blood test for hepatitis C virus (HCV) infection in baby boomers—the generation born between 1945 and 1965, who account for approximately three fourths of all chronic HCV infections in the United States—without prior ascertainment of HCV risk (see Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965). One-time HCV testing in this population could identify nearly 808,600 additional people with chronic infection. All individuals identified with HCV should be screened and/or managed for alcohol abuse, followed by referral to preventative and/or treatment services, as appropriate.
Maticic M. Lichen planus in hepatitis C virus infection: an early marker that may save lives. Acta Dermatovenerol Alp Panonica Adriat. 2007 Mar. 16(1):3-6. [Medline].
Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000 Mar 11. 355(9207):887-91. [Medline].
Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012 Feb 21. 156(4):271-8. [Medline].
Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30. 321(22):1501-6. [Medline].
Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006 Feb. 8(1):53-9. [Medline].
Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol. 2001 Feb. 44(2):159-82. [Medline].
Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004 Aug 19. 351(8):760-8. [Medline].
Rischitelli G, Harris J, McCauley L, Gershon R, Guidotti T. The risk of acquiring hepatitis B or C among public safety workers: a systematic review. Am J Prev Med. 2001 May. 20(4):299-306. [Medline].
Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology. 2001 Aug. 34(2):223-9. [Medline].
Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999 Aug 19. 341(8):556-62. [Medline].
El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003 Nov 18. 139(10):817-23. [Medline].
Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002 Nov. 36(5 Suppl 1):S30-4. [Medline].
Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997 Nov 14. 72(46):341-4. [Medline].
Nakashima K, Ikematsu H, Hayashi J, Kishihara Y, Mutsutake A, Kashiwagi S. Intrafamilial transmission of hepatitis-C virus among the population of an endemic area of Japan. JAMA. 1995 Nov 8. 274(18):1459-61. [Medline].
Osella AR, Misciagna G, Leone A, Di Leo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of Southern Italy. J Hepatol. 1997 Jul. 27(1):30-5. [Medline].
Kiyosawa K, Tanaka E, Sodeyama T, et al. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. The South Kiso Hepatitis Study Group. Gastroenterology. 1994 Jun. 106(6):1596-602. [Medline].
Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998 Dec. 28(6):1687-95. [Medline].
Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000 Jan 18. 132(2):105-11. [Medline].
Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999 Sep 16. 341(12):866-70. [Medline].
Obando J, Tortorelli K, Banner B, Stefancyk D, Bonkovsky HL. Iron: the major HFE gene mutation and chronic hepatitis C [abstract]. Gastroenterology. 2000. 118:A593.
Banner BF, Karamitsios N, Smith L, Bonkovsky HL. Enhanced phenotypic expression of alpha-1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C. Am J Gastroenterol. 1998 Sep. 93(9):1541-5. [Medline].
Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999 Apr. 29(4):1311-6. [Medline].
Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997 Jul. 27(1):201-5. [Medline].
Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology. 1998 Aug. 28(2):562-7. [Medline].
Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut. 1999 Jun. 44(6):874-80. [Medline]. [Full Text].
Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999 Apr. 29(4):1215-9. [Medline].
McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 2014 Feb 1. 174(2):204-12. [Medline].
Tucker ME. Hepatitis C viral suppression reduces liver morbidity, death. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/814456. 2013 Nov 15; Accessed: November 18, 2013.
Everson GT, Weinberg H. Living With Hepatitis C: A Survivor's Guide. 3rd ed. Long Island City, New York: Hatherleigh Health; 2002.
Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl. 2003 Nov. 9(11):S48-51. [Medline].
Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012 Aug 17. 61:1-32. [Medline]. [Full Text].
Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999 Oct. 42(10):2204-12. [Medline].
Cacoub P, Renou C, Rosenthal E, et al. The GERMIVIC. Groupe. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine (Baltimore). 2000 Jan. 79(1):47-56. [Medline].
Dervis E, Serez K. The prevalence of dermatologic manifestations related to chronic hepatitis C virus infection in a study from a single center in Turkey. Acta Dermatovenerol Alp Panonica Adriat. 2005 Sep. 14(3):93-8. [Medline].
Garcia J. Hepatitis C point-of-care tests are highly accurate. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/772679. 2012 Oct 15; Accessed: November 14, 2012.
Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med. 2012 Oct 16. 157(8):558-66. [Medline].
[Guideline] Garcia J. Hepatitis C: USPSTF recommends all baby boomers be screened. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/806836. Jun 24 2013; Accessed: Jun 26 2013.
[Guideline] Moyer VA, U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013 Sep 3. 159(5):349-57. [Medline]. [Full Text].
Lowry F. Baby boomer Hep C screening practical in emergency department. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/822310. 2014 Mar 12; Accessed: April 1, 2014.
Galbraith JW, Morgan J, Rodgers J, et al. High yield and feasibility of baby boomer birth cohort HCV screening in two urban, academic emergency departments [abstract 59]. Presented at: International Conference on Viral Hepatitis (ICVH); March 17-18, 2014; New York, NY. [Full Text].
US Food and Drug Administration. FDA approves rapid test for antibodies to hepatitis C virus. FDA News Release. June 25, 2010. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm217318.htm.
Crane M. FDA approves first genotyping test for patients with HCV. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/806646. 2013 Jun 20; Accessed: June 23, 2013.
US Food and Drug Administration. FDA approves first genotyping test for patients with hepatitis C virus. FDA News Release. 2013 Jun 20. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm357982.htm.
Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2010 Oct 1. 51(7):788-95. [Medline].
Della Rossa A, Tavoni A, Baldini C, Bombardieri S. Mixed cryoglobulinemia and hepatitis C virus association: ten years later. Isr Med Assoc J. 2001 Jun. 3(6):430-4. [Medline].
US Food and Drug Administration. 510(k) Premarket notification: Hepatiq. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K142891. Accessed: January 11, 2015.
Business Wire. Hepatiq receives FDA clearance. Hepatiq.com. Available at http://www.hepatiq.com/fdaclearshepatiq.html. 2014 Dec 19; Accessed: January 11, 2015.
HALT-C (Hepatitis C Antiviral Long-term Treatment against Cirrhosis) trial website. National Institute of Diabetes and Digestive and Kidney Diseases. Available at http://archives.niddk.nih.gov/haltctrial/displaypage.aspx?pagename=haltctrial/index.htm. Accessed: January 11, 2015.
[Guideline] AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. HCV Guidance. Available at http://www.hcvguidelines.org/full-report-view. Accessed: June 30, 2015.
Jezequel C, Bardou-Jacquet E, Desille Y, et al. Survival of patients infected by chronic hepatitis C and F0F1 fibrosis at baseline after a 15 year follow-up. Presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria.
US Food and Drug Administration. FDA approves Sovaldi for chronic hepatitis C. FDA News Release. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377888.htm. 2013 Dec 6; Accessed: December 23, 2013.
Tucker ME. FDA approves 'game changer' hepatitis C drug sofosbuvir. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/817371. 2013 Dec 6; Accessed: December 21, 2013.
Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014 Nov 15. 384(9956):1756-65. [Medline].
US Food and Drug Administration. FDA approves Viekira Pak to treat hepatitis C. FDA News Release. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm. 2014 Dec 19; Accessed: April 6, 2015.
Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986 Dec 18. 315(25):1575-8. [Medline].
Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30. 321(22):1506-10. [Medline].
Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001 Nov 15. 345(20):1452-7. [Medline].
Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000 Dec 7. 343(23):1666-72. [Medline].
Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000 Dec 7. 343(23):1673-80. [Medline].
McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19. 339(21):1485-92. [Medline].
Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998 Oct 31. 352(9138):1426-32. [Medline].
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22. 358(9286):958-65. [Medline].
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26. 347(13):975-82. [Medline].
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2. 140(5):346-55. [Medline].
Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010 Jan. 138(1):116-22. [Medline].
Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010 Jan. 138(1):108-15. [Medline].
Mira JA, Rivero-Juarez A, Lopez-Cortes LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013 Jun. 56(11):1646-53. [Medline].
Boyer JL, Chang EB, Collyar DE, et al, for the NIH Consensus Development Panel. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements. 2002 Jun 10-12. 19(3):1-46. [Medline].
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009 Sep 17. 461(7262):399-401. [Medline].
Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004 May. 126(5):1302-11. [Medline].
Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology. 1995 Nov-Dec. 42(6):907-12. [Medline].
Afdhal N, Dusheiko G, Giannini E, et al. Eltrombopag therapy for HCV-related thrombocytopenia: Final results of ENABLE 1, a phase 3 multicenter study of eltrombopag as an adjunct for antiviral treatment of hepatitis C virus-related chronic liver disease associated with thrombocytopenia. Presented at: The American Association for the Study of Liver Diseases (AASLD); November 6-9, 2011; San Francisco, CA. [Full Text].
Dusheiko G, Afdhal N, Giannini EG, et al. Results of ENABLE-2, a phase 3, placebo-controlled, multicenter study of eltrombopag, peginterferon alfa-2b, and ribavirin treatment in patients with hepatitis C and thrombocytopenia. Presented at: The 47th Annual Meeting of The European Association for the Study of the Liver (EASL); April 18-22, 2012; Barcelona, Spain. [Full Text].
Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2002 May. 26(4):731-46. [Medline].
Sarkar S, Jiang Z, Evon DM, Wahed AS, Hoofnagle JH. Fatigue before, during and after antiviral therapy of chronic hepatitis C: Results from the Virahep-C study. J Hepatol. 2012 Nov. 57(5):946-52. [Medline]. [Full Text].
A Special Meeting Review Edition: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 • Amsterdam, The NetherlandsSpecial Reporting on:• Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection• Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution ... Gastroenterol Hepatol (N Y). 2013 Jun. 9(6 Suppl 3):1-18. [Medline]. [Full Text].
Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. J Hepatol. 2015 May. 62 (5):1047-55. [Medline].
Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012 Jan 19. 366(3):216-24. [Medline].
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16. 368(20):1878-87. [Medline].
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013 May 16. 368(20):1867-77. [Medline].
MS Sulkowski, M Rodriguez-Torres, JP Lalezari, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Presented at: 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 1-5, 2013; Washington, DC. [Full Text].
Osterweil N. Ledipasvir sofosbuvir combination cuts cirrhotic Hepatitis C. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/834869. 2014 Nov 13; Accessed: November 17, 2014.
Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir/sofosbuvir fixed-dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy [abstract LB-6]. Presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7-11, 2014; Boston, MA. [Full Text].
Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015 Jul 7. 163 (1):1-13. [Medline].
Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-Generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016 Jan 1. 62 (1):32-6. [Medline].
Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24. 370(17):1594-603. [Medline].
Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24. 370(17):1604-14. [Medline].
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014 Aug. 147(2):359-365.e1. [Medline].
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May 22. 370(21):1983-92. [Medline].
Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May 22. 370(21):1973-82. [Medline].
US Food and Drug Administration. FDA approves Technivie for treatment of chronic hepatitis C genotype 4. FDA News Release. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm. July 24, 2015; Accessed: July 29, 2015.
US Food and Drug Administration. FDA approves new treatment for chronic hepatitis C genotype 3 infections. FDA News Release. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455888.htm. July 24, 2015; Accessed: July 29, 2015.
Nelson DR, Cooper JN, Lalezari JP, et al, for the ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr. 61 (4):1127-35. [Medline]. [Full Text].
Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015 Jun 20. 385 (9986):2502-9. [Medline].
Villa E, Grottola A, Buttafoco P, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol. 2001 Oct. 96(10):2973-7. [Medline].
Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003 Mar. 37(3):568-76. [Medline].
Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009 Feb. 136(2):496-504.e3. [Medline].
Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004 May 27. 350(22):2265-71. [Medline].
Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med. 2004 Aug 1. 117(3):163-8. [Medline].
Hayashi N, Kasahara A. Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Oncology. 2002. 62 Suppl 1:87-93. [Medline].
Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002 Apr. 89(4):418-22. [Medline].
Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002 Apr. 8(4):350-5. [Medline].
Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord. 2004. 4 Suppl 1:S31-8. [Medline].
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002 Apr. 122(4):889-96. [Medline].
Hui CK, Monto A, Belaye T, Lau E, Wright TL. Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut. 2003 Nov. 52(11):1644-8. [Medline]. [Full Text].
Jacobson IM, Ahmed F, Russo MW, et al. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol. 2004 Sep. 99(9):1700-5. [Medline].
Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998 Sep. 28(3):805-9. [Medline].
[Guideline] Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004 Apr. 39(4):1147-71. [Medline].
Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013 Aug. 57 Suppl 2:S32-8. [Medline]. [Full Text].
Lewis R. Hepatitis C: 6 prevention strategies that work. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/808539. 2013 Jul 26; Accessed: August 4, 2013.
Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002 May. 122(5):1303-13. [Medline].
Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther. 2004 Apr 1. 19(7):715-27. [Medline].
Barber J. Hepatitis C treated with oral nucleotide inhibitor. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/777097. 2013 Jan 03; Accessed: March 13, 2013.
Boggs W. Widespread morbilliform rash does not preclude telaprevir treatment for HCV. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/823703. 2014 Apr 16; Accessed: April 20, 2014.
Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004 Jul 29. 351(5):451-9. [Medline]. [Full Text].
Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003 Dec. 18(11-12):1071-81. [Medline].
US Food and Drug Administration. FDA approves Incivek for hepatitis C. FDA News Release. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm. 2011 May 23; Accessed: May 23, 2011.
Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013 Jan. 11(1):81-87.e4; quiz e5. [Medline].
Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology. 2011 Sep. 141(3):881-889.e1. [Medline].
Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013 Jan 3. 368(1):34-44. [Medline].
Volansky R. HCV recommendations updated to include patients with limited resources. Healio.com. Available at http://www.healio.com/infectious-disease/hepatitis-c/news/online/%7B7377b5a9-e35d-4143-98c4-b86c0d552596%7D/hcv-recommendations-updated-to-include-patients-with-limited-resources. 2014 Aug 11; Accessed: August 16, 2014.
Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013 May 16. 368(20):1867-77. [Medline].
Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004 Sep 3. 18(13):F27-36. [Medline].
Liu CH, Liang CC, Liu CJ, et al. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis. 2010 Sep 1. 51(5):541-9. [Medline].
Lowes R. CDC urges second test to catch hepatitis C infection. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/803727. 2013 May 7; Accessed: May 8, 2013.
Lowes R. FDA OKs first combo drug (Harvoni) for hepatitis C. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/833108. 204 Oct 10; Accessed: October 20, 2014.
Lowry F. Hepatitis C treatment viable in primary care. Medscape Medical News from WebMD. Available at http://www.medscape.com/viewarticle/822130. 2014 Mar 18; Accessed: March 18, 2014.
McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009 Apr 30. 360(18):1827-38. [Medline].
Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc. 2003 Dec. 35(8):3042-4. [Medline].
Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 Jul. 8(7):623-9. [Medline].
Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31. 364(13):1195-206. [Medline].
Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004 Jan 27. 77(2):190-4. [Medline].
Saag MS. Quantum leaps, microeconomics, and the treatment of patients with hepatitis C and HIV coinfection. JAMA. 2014 Jul 23-30. 312(4):347-8. [Medline].
Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology. 2003 Mar. 124(3):642-50. [Medline].
Smith M. Combo cures HCV in HIV patients. MedPage Today. Available at http://www.medpagetoday.com/meetingcoverage/iac/46843?xid=nl_mpt_DHE_2014-07-21&utm_content=&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=ST&eun=g808581d0r&userid=808581&email=cwojdylo%40webmd.net&mu_id=6095519&utm_term=Daily. 2014 Jul 19; Accessed: July 28, 2014.
Smith M. Guidelines: treat sickest HCV patients first. MedPage Today. Available at http://www.medpagetoday.com/InfectiousDisease/Hepatitis/47152. 2014 Aug 11; Accessed: August 16, 2014.
Strazzula L, Pratt DS, Zardas J, Chung RT, Thiim M, Kroshinsky D. Widespread morbilliform eruption associated with telaprevir: use of dermatologic consultation to increase tolerability. JAMA Dermatol. 2014 Jul. 150(7):756-9. [Medline].
Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014 Jul 23-30. 312(4):353-61. [Medline].
Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology. 1997 Sep. 26(3):747-54. [Medline].
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004 Jul 29. 351(5):438-50. [Medline].
Vital signs: evaluation of hepatitis C virus infection testing and reporting - eight U.S. sites, 2005-2011. MMWR Morb Mortal Wkly Rep. 2013 May 10. 62(18):357-61. [Medline].
Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016 Jan 11. [Medline].
Wyles DL, Ruane PJ, Sulkowski MS, et al, for the ALLY-2 Investigators. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015 Aug 20. 373 (8):714-25. [Medline]. [Full Text].